<DOC>
	<DOC>NCT00712881</DOC>
	<brief_summary>Evaluate the efficacy and safety of treatment with MYOCET® in combination with Cyclophosphamide and Trastuzumab, 4 cycles, followed by Docetaxel plus Trastuzumab, 4 cycles, in women with stage II or III breast cancer whose tumour overexpresses the HER2 gene.</brief_summary>
	<brief_title>Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Patients With HER2-Positive Breast Cancer</brief_title>
	<detailed_description>A multicentre, open-label, randomized, Phase 2 study to evaluate the efficacy and safety of treatment with MYOCET® in combination with cyclophosphamide and trastuzumab versus free doxorubicin in combination with cyclophosphamide, each followed by docetaxel and trastuzumab, in women with stage II or III breast cancer whose tumour overexpresses the HER2 gene.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Main Treatmentnaive patients with stage II or III invasive breast cancer (proven histologically/cytologically) and with tests showing an overexpressing of human epidermal growth factor receptor 2 (HER2). Patients have at least one bidimensionally measurable lesion according to the WHO criteria. The patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. The patient has an LVEF of at least 55% as assessed by multiplegated acquisition (MUGA) scan (preferred) or echocardiography. The patient has hematology and serum chemistry laboratory test results within specific protocoldefined ranges. Women of childbearing potential must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the treatment period and for 6 months after the last administration of study drug. Main The patient: Has received previous cancer therapy for breast cancer. Has any history of CHF, angina pectoris, or myocardial infarction. Has uncontrolled hypertension. Has infection, peptic ulcer, or unstable diabetes mellitus. Has been treated with live virus vaccines within 8 weeks before the first administration of study drug. Has impaired hepatic or renal function. Is a pregnant or lactating woman. (Any women becoming pregnant during the study will be withdrawn from the study.) Has used an investigational drug within one month before the screening visit. Has a known hypersensitivity to any of the study drugs or to their active ingredients. Has an inflammatory breast cancer. Has had any other malignancies within five years (except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer).</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>